- In May 2023, the FDA approval of Paxlovid as the first oral antiviral pill for mild-to-moderate COVID-19 treatment in high-risk adults marked a major milestone in the antiviral drugs market. This approval increased market penetration of oral antivirals in the U.S. and globally, driving innovation and competition while reinforcing the shift toward more convenient, outpatient COVID-19 treatment options, thereby further propelling market expansion
- In January 2023, Merck, known as MSD, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago Biosciences, Inc. (Nasdaq: IMGO), at a purchase price of USD 36.00 per share in cash, without interest and subject to deduction for any required tax withholding. The acquisition will help in the growth of the revenue
- In January 2022, the launch of Molnupiravir by Lupin Limited in India under emergency use authorization significantly impacted the antiviral drugs market by expanding treatment options for COVID-19 patients at high risk of disease progression. This introduction helped boost the demand for oral antiviral therapies, especially in emerging markets, accelerating market growth amid the ongoing pandemic
- In April 2021, Zydus Pharmaceuticals, Inc. announced that it had received restricted emergency use approval from the Drug Controller General of India (DCGI) to use the antiviral drug Virafin for the treatment of moderate COVID-19 infections. This will help the company to increase its global presence and reputation in other regions of the globe
